ReviewCellular & molecular immunology2011
The inflammasomes in health and disease: from genetics to molecular mechanisms of autoinflammation and beyond.
Review in Cellular & molecular immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02539147 (Characterization of Non-canonical Way in Inflammasome Monocytes of Patients With Severe Sepsis), which is not on this map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Characterization of Non-canonical Way in Inflammasome Monocytes of Patients With Severe Sepsis
Who cites it
57 citing papers in PubMed, 102 citations in OpenAlex.
- NLRP3 inflammasome and hearing loss: from mechanisms to therapies.Journal of neuroinflammation · 2025Review
- Advances in Nano-Immunomodulatory Systems for the Treatment of Acute Kidney Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- The PGAM5-NEK7 interaction is a therapeutic target for NLRP3 inflammasome activation in colitis.Acta pharmaceutica Sinica. B · 2025Article
- Implication of the LRR Domain in the Regulation and Activation of the NLRP3 Inflammasome.Cells · 2024Review
- Renal macrophages and NLRP3 inflammasomes in kidney diseases and therapeutics.Cell death discovery · 2024Review
- New Insights on NLRP3 Inflammasome: Mechanisms of Activation, Inhibition, and Epigenetic Regulation.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2024Review
- Osteostatin Mitigates Gouty Arthritis through the Inhibition of Caspase-1 Activation and Upregulation of Nrf2 Expression.International journal of molecular sciences · 2024Article
- Case Report: A neonatal case of cryopyrin-associated periodic syndrome with severe funisitis and neonatal asphyxia.Frontiers in pediatrics · 2024Article
- Microbial sensing in the intestine.Protein & cell · 2023Review
- Allergen-induced CD11c + dendritic cell pyroptosis aggravates allergic rhinitis.Cell communication and signaling : CCS · 2023Article
- A novel sorbicillinoid compound as a potent anti-inflammation agent through inducing NLRP3 protein degradation.British journal of pharmacology · 2023Article
- Targeting shared molecular etiologies to accelerate drug development for rare diseases.EMBO molecular medicine · 2023Review
- Hydrogen-Rich Saline-A Novel Neuroprotective Agent in a Mouse Model of Experimental Cerebral Ischemia via the ROS-NLRP3 Inflammasome Signaling Pathway In Vivo and In Vitro.Brain sciences · 2023Article
- Mitochondrial dysfunction in hearing loss: Oxidative stress, autophagy and NLRP3 inflammasome.Frontiers in cell and developmental biology · 2023Review
- Article
- CCDC50 suppresses NLRP3 inflammasome activity by mediating autophagic degradation of NLRP3.EMBO reports · 2022Article
- NLRP3 inflammasome as a novel therapeutic target for heart failure.Anatolian journal of cardiology · 2022Article
- An Atypical Autoinflammatory Disease Due to an LRR Domain NLRP3 Mutation Enhancing Binding to NEK7.Journal of clinical immunology · 2022Article
- The NLRP3 inflammasome mediates liver failure by activating procaspase-1 and pro-IL-1 β and regulating downstream CD40-CD40L signaling.The Journal of international medical research · 2021Article
- Angiotensin-II activates vascular inflammasome and induces vascular damage.Vascular pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nucleotide-binding oligomerization domain (NOD)-containing protein-like receptors (NLRs) are a recently discovered class of innate immune receptors that play a crucial role in initiating the inflammatory response following pathogen recognition. Some NLRs form the framework for cytosolic platforms called inflammasomes, which orchestrate the early inflammatory process via IL-1β activation. Mutations and polymorphisms in NLR-coding genes or in genetic loci encoding inflammasome-related proteins correlate with a variety of autoinflammatory diseases. Moreover, the activity of certain inflammasomes is associated with susceptibility to infections as well as autoimmunity and tumorigenesis. In this review, we will discuss how identifying the genetic characteristics of inflammasomes is assisting our understanding of both autoinflammatory diseases as well as other immune system-driven disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.